Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs


There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk’s new data is a meaningful start…

Share post:



More like this

Here’s what’s next for Paramount after Skydance deal is stopped in its tracks

Shari Redstone's National Amusements stopped deal talks between Paramount...

Cramer examines Fed decision, booming tech stocks

CNBC's Jim Cramer said the Federal Reserve and the...